Why the study?
Data reflecting the clinical benefit of procedural improvements in real-world transcatheter aortic valve implantation practice were sparse.
Does TAVI performed in the recent era (2016-2018) improve 1-year clinical outcomes compared to the earlier era (2010-2012) in real-world patients?
Does TAVI performed in the recent era (2016-2018) improve 1-year clinical outcomes compared to the earlier era (2010-2012) in real-world patients?
Answers are grounded in this paper and cite their sources.
Real-world outcomes of TAVI in Italy have significantly improved over time, with lower 1-year mortality and heart failure rehospitalization in the 2016-2018 era compared to 2010-2012, despite similar patient age and risk profiles.
BACKGROUND: Data reflecting the benefit of procedural improvements in real-world transcatheter aortic valve implantation (TAVI) practice are sparse. AIMS: To compare outcomes and trends of two TAVI eras from real Italian practice. METHODS: A total of 1811 and 2939 TAVI patients enrolled in the national, prospective OBSERVANT and OBSERVANT II studies in 2010-2012 and 2016-2018, respectively, were compared in a cohort study. Outcomes were adjusted using inverse propensity of treatment weighting and propensity score matching. RESULTS: The median age (83.0 (79.0-86.0) vs. 83.0 (79.0-86.0)) and EuroSCORE II (5.2 (3.2-7.7) vs. 5.1 (3.1-8.1)) of OBSERVANT and OBSERVANT II patients were similar. At 1 year, patients of the OBSERVANT II study had a significantly lower risk of all-cause death (10.6% vs. 16.3%, Hazard Ratio (HR) 0.63 (95% Confidence Interval (CI) 0.52-0.76)) and rehospitalization for heart failure (HF) (14.3% vs. 19.5%, Sub-distribution HR 0.71 (95%CI 0.60-0.84)), whereas rates of stroke (3.1% vs. 3.6%) and permanent pacemaker implantation (PPI) (16.6% vs. 18.0%) were comparable between study groups. CONCLUSIONS: Age and risk profile among patients undergoing TAVI in Italy remained substantially unchanged between the 2010-2012 and 2016-2018 time periods. After adjustment, patients undergoing TAVI in the most recent era had lower risk of all-cause death and rehospitalization for HF at 1 year, whereas rates of stroke and PPI did not differ significantly.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: